Brokerages Anticipate Spero Therapeutics Inc (SPRO) Will Post Earnings of -$0.74 Per Share

Share on StockTwits

Brokerages expect Spero Therapeutics Inc (NASDAQ:SPRO) to announce earnings per share (EPS) of ($0.74) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Spero Therapeutics’ earnings, with estimates ranging from ($0.78) to ($0.70). Spero Therapeutics also posted earnings of ($0.74) per share in the same quarter last year. The firm is expected to report its next quarterly earnings report on Thursday, May 9th.

On average, analysts expect that Spero Therapeutics will report full year earnings of ($3.25) per share for the current financial year, with EPS estimates ranging from ($4.08) to ($2.59). For the next fiscal year, analysts anticipate that the company will report earnings of ($3.82) per share, with EPS estimates ranging from ($4.06) to ($3.51). Zacks’ earnings per share averages are an average based on a survey of research firms that follow Spero Therapeutics.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings results on Thursday, March 14th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.15. The business had revenue of $1.69 million during the quarter, compared to analyst estimates of $0.84 million. Spero Therapeutics had a negative net margin of 1,402.91% and a negative return on equity of 52.22%.

Several equities analysts recently weighed in on SPRO shares. ValuEngine lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 2nd. Zacks Investment Research lowered shares of Spero Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, January 12th. Oppenheimer set a $30.00 price objective on shares of Spero Therapeutics and gave the company a “buy” rating in a research report on Sunday, January 13th. Finally, Cantor Fitzgerald started coverage on shares of Spero Therapeutics in a research report on Monday, February 4th. They set a “buy” rating and a $27.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $20.65.

SPRO traded up $0.16 during midday trading on Friday, hitting $13.14. 1,218 shares of the company’s stock traded hands, compared to its average volume of 64,938. The firm has a market cap of $223.16 million, a PE ratio of -0.73 and a beta of 2.96. Spero Therapeutics has a one year low of $5.52 and a one year high of $19.00.

Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its stake in shares of Spero Therapeutics by 35.6% in the second quarter. BlackRock Inc. now owns 341,999 shares of the company’s stock worth $5,017,000 after acquiring an additional 89,698 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Spero Therapeutics during the 3rd quarter worth $126,000. Bridgeway Capital Management Inc. grew its holdings in shares of Spero Therapeutics by 43.7% during the 3rd quarter. Bridgeway Capital Management Inc. now owns 78,579 shares of the company’s stock worth $826,000 after purchasing an additional 23,879 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Spero Therapeutics during the 3rd quarter worth $462,000. Finally, Aquilo Capital Management LLC grew its holdings in shares of Spero Therapeutics by 91.9% during the 3rd quarter. Aquilo Capital Management LLC now owns 799,691 shares of the company’s stock worth $8,405,000 after purchasing an additional 383,000 shares in the last quarter. 51.00% of the stock is currently owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. Its product candidate includes SPR994, an oral carbapenem-class antibiotic to treat MDR gram-negative infections for adults; and SPR741, which is in Phase Ib clinical trial to treat MDR gram-negative infections in the hospital setting.

Further Reading: Should I invest in “strong buy” stocks?

Get a free copy of the Zacks research report on Spero Therapeutics (SPRO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Spero Therapeutics (NASDAQ:SPRO)

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

AtriCure  Rating Increased to Buy at BidaskClub
AtriCure Rating Increased to Buy at BidaskClub
Adverum Biotechnologies  Stock Rating Upgraded by Zacks Investment Research
Adverum Biotechnologies Stock Rating Upgraded by Zacks Investment Research
PennyMac Mortgage Investment Trust  Receives Average Recommendation of “Buy” from Analysts
PennyMac Mortgage Investment Trust Receives Average Recommendation of “Buy” from Analysts
Critical Review: Bright Mountain Media  & PROS
Critical Review: Bright Mountain Media & PROS
Veracyte  Raised to “Buy” at BidaskClub
Veracyte Raised to “Buy” at BidaskClub
Zynerba Pharmaceuticals  Rating Increased to Buy at ValuEngine
Zynerba Pharmaceuticals Rating Increased to Buy at ValuEngine


© 2006-2019 Ticker Report